Effect of dapagliflozin on outcomes in women and men with heart failure with reduced ejection fraction in the DAPA-HF trial

被引：0
|
作者：
Butt, J. H. [1 ]
Kober, L. [1 ]
Docherty, K. F. [2 ]
Inzucchi, S. E. [3 ]
Kosiborod, M. N. [4 ]
Langkilde, A. M. [5 ]
Martinez, F. [6 ]
Bengtsson, O. [5 ]
Ponikowski, P. [7 ]
Demets, D. L. [8 ]
Sjostrand, M. [5 ]
Sabatine, M. S. [9 ]
Solomon, S. D. [9 ]
Jhund, P. S. [2 ]
Mcmurray, J. John [2 ]
机构：
[1] Univ Copenhagen, Dept Cardiol, Copenhagen, Denmark
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Yale Univ, Sch Med, Dept Endocrinol, New Haven, CT USA
[4] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[5] AstraZeneca, Gothenburg, Sweden
[6] Univ Cordoba, Cordoba, Argentina
[7] Wroclaw Med Univ, Warsaw, Poland
[8] Univ Wisconsin, Madison, WI 53706 USA
[9] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
90
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [41] Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
    Camps-Vilaro, Anna
    Delgado-Jimenez, Juan F.
    Farre, Nuria
    Tizon-Marcos, Helena
    Alvarez-Garcia, Jesus
    Cinca, Juan
    Degano, Irene R.
    Marrugat, Jaume
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 15
  • [42] Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF
    Docherty, K. F.
    Vaduganathan, M.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Bengtsson, O.
    Ponikowski, P.
    Sabatine, M. S.
    Sjostrand, M.
    Solomon, S. D.
    Langkilde, A. M.
    Jhund, P. S.
    Mcmurray, J. J. V. John J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 57 - 57
  • [43] Translating findings from the landmark DAPA-HF study: a multinational cost-effectiveness analysis of dapagliflozin in the treatment of heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Mcewan, P.
    Darlington, O.
    Jhund, P.
    Docherty, K.
    Bohm, M.
    Petrie, M.
    Bergenheim, K.
    Qin, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 272 - 273
  • [44] MATCHING ADJUSTED INDIRECT COMPARISON BETWEEN DAPA-HF AND PARADIGM-HF FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    Qin, L.
    Young, R.
    Darlington, O.
    Song, B.
    McEwan, P.
    VALUE IN HEALTH, 2020, 23 : S489 - S489
  • [45] Dapagliflozin and DAPA-HF: from glycaemic control to heart failure therapy
    Fisher, Miles
    PRACTICAL DIABETES, 2019, 36 (06) : 192 - 193
  • [46] Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
    Wang, Xiaowen
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Hegde, Sheila M.
    Pabon, Maria
    Kulac, Ian J.
    Vardeny, Orly
    O'Meara, Eileen
    Zieroth, Shelley
    Katova, Tzvetana
    McGrath, Martina M.
    Pouleur, Anne-Catherine
    Jhund, Pardeep S.
    Desai, Akshay S.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    de Boer, Rudolf A.
    Kober, Lars
    Sabatine, Marc S.
    Martinez, Felipe A.
    Ponikowski, Piotr
    Shah, Sanjiv J.
    Hernandez, Adrian F.
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    Lam, Carolyn S. P.
    CIRCULATION, 2023, 147 (08) : 624 - 634
  • [47] The relationships between circulating biomarkers of iron deficiency and outcomes in patients with heart failure and reduced ejection fraction: insights from DAPA-HF
    Docherty, Kieran
    Brennan, Alice
    Sukumar, Shivasankar
    Welsh, Paul
    Ponikowski, Piotr
    Petrie, Mark
    Cleland, John
    Solomon, Scott
    Jhund, Pardeep
    McMurray, John
    CIRCULATION, 2024, 150
  • [48] Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
    Docherty, Kieran F.
    Jhund, Pardeep S.
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Martinez, Felipe A.
    Ponikowski, Piotr
    DeMets, David L.
    Sabatine, Marc S.
    Bengtsson, Olof
    Sjostrand, Mikaela
    Langkilde, Anna Maria
    Desai, Akshay S.
    Diez, Mirta
    Howlett, Jonathan G.
    Katova, Tzvetana
    Ljungman, Charlotta E. A.
    O'Meara, Eileen
    Petrie, Mark C.
    Schou, Morten
    Verma, Subodh
    Pham Nguyen Vinh
    Solomon, Scott D.
    McMurray, John J., V
    EUROPEAN HEART JOURNAL, 2020, 41 (25) : 2379 - 2392
  • [49] A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
    McMurray, John J., V
    DeMets, David L.
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Langkilde, Anna M.
    Martinez, Felipe A.
    Bengtsson, Olof
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjostrand, Mikaela
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (05) : 665 - 675
  • [50] Initial Decline (Dip) in Estimatec Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
    Adamson, Carly
    Docherty, Kieran F.
    Heerspink, Hiddo J. L.
    de Boer, Rudolf A.
    Damman, Kevin
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Martinez, Felipe A.
    Petrie, Mark C.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Schou, Morten
    Solomon, Scott D.
    Verma, Subodh
    Bengtsson, Olof
    Langkilde, Anna Maria
    Sjostrand, Mikaela
    Vaduganathan, Muthiah
    Jhund, Pardeep S.
    McMurray, John J., V
    CIRCULATION, 2022, 146 (06) : 438 - 449
12345